Last reviewed · How we verify

Docetaxel, Capecitabine and Oxaliplatin

Asan Medical Center · Phase 1 active Small molecule

Docetaxel, Capecitabine and Oxaliplatin is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 1 development.

At a glance

Generic nameDocetaxel, Capecitabine and Oxaliplatin
SponsorAsan Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Docetaxel, Capecitabine and Oxaliplatin

What is Docetaxel, Capecitabine and Oxaliplatin?

Docetaxel, Capecitabine and Oxaliplatin is a Small molecule drug developed by Asan Medical Center.

Who makes Docetaxel, Capecitabine and Oxaliplatin?

Docetaxel, Capecitabine and Oxaliplatin is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).

What development phase is Docetaxel, Capecitabine and Oxaliplatin in?

Docetaxel, Capecitabine and Oxaliplatin is in Phase 1.

Related